Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · Real-Time Price · USD
29.40
-0.29 (-0.98%)
At close: Oct 29, 2025, 4:00 PM EDT
29.60
+0.20 (0.68%)
After-hours: Oct 29, 2025, 4:07 PM EDT
Rigel Pharmaceuticals Revenue
Rigel Pharmaceuticals had revenue of $101.69M in the quarter ending June 30, 2025, with 176.01% growth. This brings the company's revenue in the last twelve months to $267.92M, up 105.62% year-over-year. In the year 2024, Rigel Pharmaceuticals had annual revenue of $179.28M with 54.71% growth.
Revenue (ttm)
$267.92M
Revenue Growth
+105.62%
P/S Ratio
1.97
Revenue / Employee
$1,633,665
Employees
164
Market Cap
525.92M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 179.28M | 63.40M | 54.71% |
| Dec 31, 2023 | 115.88M | 140.00K | 0.12% |
| Dec 31, 2022 | 115.74M | -22.99M | -16.57% |
| Dec 31, 2021 | 138.74M | 30.12M | 27.72% |
| Dec 31, 2020 | 108.62M | 49.33M | 83.21% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
RIGL News
- 8 hours ago - Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update - PRNewsWire
- 21 days ago - Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS - PRNewsWire
- 26 days ago - Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 4 weeks ago - Rigel Pharmaceuticals: Strong Growth Trajectory And Commercial Expansion - Seeking Alpha
- 2 months ago - Rigel to Participate in Upcoming September Investor Conferences - PRNewsWire
- 2 months ago - Rigel Pharmaceuticals: Q2 Earnings Fuel A Potential Breakout - Seeking Alpha
- 3 months ago - Rigel Pharmaceuticals, Inc. (RIGL) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update - PRNewsWire